-1753361094794.webp&w=3840&q=75)
2025 NOSCM | Updates on ROS-1, RET, BRAF, MET & NTRK
Overview
Dr. Janakiram Subramanian discussed KRAS and HER2 mutations, noting the potential of new agents like zongertinib.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Janakiram Subramanian, MD, MPH
Date of Release
July 24th, 2025
-1755990775594.webp&w=3840&q=75)
-1755990700517.webp&w=3840&q=75)